Viferon-2 500000ME number 10 candles
Pharmacological propertiesInterferon alpha-2b human recombinant has immunomodulatory, antiviral, anti-proliferative properties. The immunomodulating properties of interferon, such as the enhancement of the phagocytic activity of macrophages, the increase in the specific cytotoxicity of lymphocytes to target cells, determine its mediated antibacterial activity.
In the presence of ascorbic acid and alpha-tocopherol acetate, the specific antiviral activity of interferon increases, and its immunomodulatory effect is enhanced, which makes it possible to increase the effectiveness of the body’s own immune response to pathogenic microorganisms. The use of the drug increases the level of class A secretory immunoglobulins, normalizes the level of immunoglobulin E, restores the functioning of the endogenous interferon system. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane-stabilizing, and regenerating properties. It has been established that when using Viferon there are no side effects arising from the parenteral administration of interferon preparations, no antibodies are formed that neutralize the antiviral activity of interferon. The use of the drug allows to reduce therapeutic doses of antibacterial and hormonal drugs, as well as reduce the toxic effects of this therapy.
Cocoa butter contains phospholipids, which allow not to use synthetic toxic emulsifiers in production, and the presence of polyunsaturated fatty acids facilitates the introduction and dissolution of the drug.
1 suppository VIFERON&№174; 500000 IU contains the active substance: interferon alpha-2b human recombinant 500,000 IU, excipients: alpha-tocopherol acetate 0.055 g, ascorbic acid 0.0081 g, sodium ascorbate 0,0162 g, disodium edetate dihydrate 0,0001 g , polysorbate - 80 0.0001 g, cocoa butter base and confectionary fat up to 1 g.
Indications for use
in the treatment of various infectious and inflammatory diseases in children, including newborns and premature infants: acute respiratory viral infections, including influenza,including those complicated by bacterial infection, pneumonia (bacterial, viral, chlamydia), meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasma);
in the complex therapy of chronic viral hepatitis B, C, D in children and adults, including in combination with the use of plasmapheresis and hemosorption, in chronic viral hepatitis of marked activity, including those complicated by liver cirrhosis;
in complex therapy in adults, including pregnant women, with urogenital infection (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellez, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis), primary or relapse, in your surgery, in a case of relapse, recurrent vaginal candidiasis, mycoplasmosis form, mild and moderate course, including urogenital form;
in the treatment of acute respiratory viral infections, including influenza, including those complicated by bacterial infection in adults.
ContraindicationsHypersensitivity to any of the components of the drug.
Use during pregnancy and lactation
The drug is approved for use from the 14th week of pregnancy. There are no restrictions for use during lactation.
2 years. Do not use the drug after the expiration date.
At a temperature of 2 to 8 ° C, protected from light.
Keep out of reach of children.
It is a pharmaceutical drug. Use only as directed by your doctor.
Attention! During storage must comply with the temperature regime.